Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ESTRO-EANO guideline on target delineation and radiotherapy for IDH-mutant WHO CNS grade 2 and 3 diffuse glioma.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology - 1 Jan 2025

Baumert Brigitta G, P M Jaspers Jaap, Keil Vera C, Galldiks Norbert, Izycka-Swieszewska Ewa, Timmermann Beate, Grosu Anca L, Minniti Giuseppe, Ricardi Umberto, Dhermain Frédéric, Weber Damien C, van den Bent Martin, Rudà Roberta, Niyazi Maximilian, Erridge Sara

Abstract excerpt

PURPOSE: This guideline will discuss radiotherapeutic management of IDH-mutant grade 2 and grade 3 diffuse glioma, using the latest 2021 WHO (5th) classification of brain tumours focusing on: imaging modalities, tumour volume delineation, irradiation dose and fractionation. METHODS: The ESTRO Guidelines Committee, CNS subgroup, nominated 15 European experts who identified questions for this guideline. Four...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Glioma

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Neoplasm Grading

Share to Radiotherapy Dosage

Share to Tumor Burden

Source

Identifiers

PMID: 39454886
DOI: 10.1016/j.radonc.2024.110594

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ESTRO-EANO guideline on target delineation and radiotherapy for IDH-mutant WHO CNS grade 2 and 3 diffuse glioma.PMID 39454886Read ↗

Changes in clinical management of diffuse IDH-mutated lower-grade gliomas: patterns of care in a 15-year period.Semantic proximity Read ↗

A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults.Semantic proximity Read ↗

Current Considerations in the Treatment of Grade 3 Gliomas.Semantic proximity Read ↗

Imaging-Based Versus Pathologic Survival Stratifications of Diffuse Glioma According to the 2021 WHO Classification System.Semantic proximity Read ↗

Rethinking extent of resection of contrast-enhancing and non-enhancing tumor: different survival impacts on adult-type diffuse gliomas in 2021 World Health Organization classification.Semantic proximity Read ↗

Multidisciplinary consensus recommendations for the management of IDH-mutant grade 2 gliomas in Spain: a Delphi study.Semantic proximity Read ↗

Current Treatment Options for Adult Grade 2 IDH-mutant Diffuse Gliomas in the Vorasidenib Era: Patient Selection, Sequencing, and Practical Management.Semantic proximity Read ↗

IDH status shapes glioma oncotopy: voxel-wise mapping of 644 adult diffuse gliomas.Semantic proximity Read ↗

Analysis of safety and efficacy of proton radiotherapy for IDH-mutated glioma WHO grade 2 and 3.Semantic proximity Read ↗

Neuroimaging features of diffuse hemispheric glioma, H3 G34-mutant: A case series and systematic review.Semantic proximity Read ↗

Long-term outcomes in IDH-wildtype (IDH-wt) gliomas with historical WHO grade 2 and 3 histology.Semantic proximity Read ↗

Volumetric response and pattern of failure of histone altered high grade glioma in adults following management with radiation therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.